Ultrastructural abnormalities of astrocytes in the hippocampus in schizophrenia and duration of illness: A postortem morphometric study

World Journal of Biological Psychiatry

Volumn 11, Issue 2 PART 2, 2010, Pages 282-292

  Kolomeets, Natalya S ^a   Uranova, Natalya ^a  

^a MENTAL HEALTH RESEARCH CENTER   (Russian Federation)

Author keywords

Astrocytes; Hippocampus; Morphometry; Schizophrenia; Ultrastructure

Indexed keywords

LIPOFUSCIN;

ARTICLE; ASTROCYTE; AUTOPSY; BRAIN MITOCHONDRION; CELL DENSITY; CELL GRANULE; CELL NUCLEUS; CELL SIZE; CELL ULTRASTRUCTURE; CELL VOLUME; COMPARATIVE STUDY; CYTOPLASM; DISEASE DURATION; GROUPS BY AGE; HIPPOCAMPUS; HUMAN; SCHIZOPHRENIA;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ASTROCYTES; CASE-CONTROL STUDIES; CELL NUCLEUS; CYTOPLASM; DISEASE PROGRESSION; FEMALE; HIPPOCAMPUS; HUMANS; LIPOFUSCIN; MALE; MICROSCOPY, ELECTRON; MIDDLE AGED; MITOCHONDRIA; SCHIZOPHRENIA; SEX FACTORS; YOUNG ADULT;

EID: 77950825033     PISSN: 15622975     EISSN: 18141412     Source Type: Journal    
DOI: 10.3109/15622970902806124     Document Type: Article

References (65)

1. Amenta F, Bronzetti E, Sabbatini M, Vega JA. 1998. Astrocyte changes in aging cerebral cortex and hippocampus: a quantitative immunohistochemical study. Microsc Res Tech 43: 29-33.
2. Arnold SE, Franz BR, Gur RC, Gur RE, Shapiro RM, Moberg PJ, et al. 1995. Smaller neuron size in schizophrenia in hippocampal subfields that mediate cortical-hippocampal interactions. Am J Psychiatry 152:738-748.
3. Arnold SE, Franz BR, Trojanowski JQ, Moberg PJ, Gur RE. 1996. Glial fibrillary acidic protein-immunoreactive astrocytosis in elderly patients with schizophrenia and dementia. Acta Neuropathol (Berlin) 91:269-277. (Pubitemid 26042219)
4. Balijepalli S, Kenchappa RS, Boyd MR, Ravindranath V. 2001. Protein thiol oxidation by haloperidol results in inhibition of mitochondrial complex I in brain regions: comparison with atypical antipsychotics. Neurochem Int 38:425-435. (Pubitemid 32166900)
5. Bendikov I, Nadri C, Amar S, Panizzutti R, De Miranda J, Wolosker H, et al. 2007. A CSF and postmortem brain study of D-serine metabolic parameters in schizophrenia. Schizophr Res 90:41-51. (Pubitemid 46177566)
6. Benes FM, Sorensen I, Bird ED. 1991. Reduced neuronal size in posterior hippocampus of schizophrenic patients. Schizophr Bull 17:597-608.
7. Benes FM, Todtenkopf MS, Kostoulacos P. 2001. GluR5,6,7 subunit immune-reactivity on apical pyramidal cell dendrites in hippocampus of schizophrenics and manic-depressives. Hippocampus 11:482-491.
8. Cavalier L, Jazin E, Eriksson I, Prince J, Båve B, Oreland L, Gyllensten U. 1995. Decreased cytochrome-c oxidase activity and lack of age related accumulation of mtDNA in the brains of schizophrenics. Genomics 29:217-228.
9. Chakos MH, Schobel SA, Gu H, Gerig G, Bradford D, Charles C, et al. 2005. Duration of illness and treatment effects on hippocampal volume in male patients with schizophrenia. Br J Psychiatr 186:26-31. (Pubitemid 40070540)
10. Chambers JS, Thomas D, Saland L, Neve RL, Perrone-Bizzozero NI. 2005. Growth-associated protein 43 (GAP-43) and synaptophysin alterations in the dentate gyrus of patients with schizophrenia. Prog Neuropsychopharm Biol Psychiatry 29:283-290. (Pubitemid 40202915)
11. Cotter D, Kerwin R, Doshi B, Martin CS, Everall IP. 1997. Alterations in hippocampal non-phosphorylated MAP2 protein expression in schizophrenia. Brain Res 765:238-246. (Pubitemid 27397619)
12. Cotter DR, Pariante CM, Everall IP. 2001. Glial cell abnormalities in major psychiatric disoders: The evidence and implications. Brain Res Bull 55:585-595.
13. Coyle JT, Tsai G. 2004. The NMDA receptor glycine modulatory site: a therapeutic target for improving cognition and reducing negative symptoms in schizophrenia. Psychopharmacol (Berlin) 174:32-38. (Pubitemid 38925088)
14. Davis JM. 1974. Dose equivalent of the antipsychotic drugs. J Psychiatr Res 11:65-69.
15. Deloncle R, Huguet F, Fernandez B, Quellard N, Babin P, Guillard O. 2001. Ultrastructural study of rat hippocampus after chronic administration of aluminum L-glutamate: an acceleration of the aging process. Exp Gerontol 36:231-244. (Pubitemid 32162479)
16. Eastwood SL, Harrison PJ. 1999. Detection and quantification of hippocampal synaptophysin messenger RNA in schizophrenia using autoclaved, formalin-fixed, paraffin wax-embedded sections. Neuroscience 93:99-106.
17. Ghose S,Weickert CS, Colvin SM, Coyle JT, Herman MM, Hyde TM, et al. 2004. Glutamate carboxypeptidase II gene expression in the human frontal and temporal lobe in schizophrenia. Neuropsychopharmacology 29:117-125. (Pubitemid 38068021)
18. Gothelf D, Soreni N, Nachman RP, Tyano S, Hiss Y, Reiner O et al. 2000. Evidence for the involvement of the hippocampus in the pathophysiology of schizophrenia. Eur Neuropsychopharmacol 10:389-395.
19. Gundersen HJG, Bagger P, Bendtsen TF, Evans SM, Korbo L, Marcusen N, et al. 1988. The new stereological tools: Dissector, fractionator, nucleator point sampled intercepts and their use in pathological research and diagnosis. Acta Pathol Microbiol Immunol Scand 96:857-881.
20. Hansson E, Rönnbäck L. 2003. Glial neuronal signaling in the central nervous system. FASEB J 17:341-348. (Pubitemid 36292950)
21. Harrison PJ, Eastwood SL. 2001. Neuropathological studies of synaptic connectivity in the hippocampal formation in schizophrenia. Hippocampus 11:508-519.
22. Harrison PJ, Law AJ, Eastwood SL. 2003. Glutamate receptors and transporters in the hippocampus in schizophrenia. Ann NY Acad Sci 1003:94-101.
23. Haydon PG, Carmignoto G. 2006. Astrocyte control of synaptic transmission and neurovascular coupling. Physiol Rev 86: 1009-1031. (Pubitemid 44033387)
24. Hovard CV, Reed MG. 1998. Unbiased stereology. Threedimensional measurement in microscopy. New York: Springer.
25. Johnston-Wilson NL, Sims CD, Hofmann JP, Anderson L, Shore AD, Torrey EF, et al. 2000. Disease-specific alterations in frontal cortex brain proteins in schizophrenia, bipolar disorder, and major depressive disorder. The Stanley Neuropathology Consortium. Mol Psychiatry 5:142-149.
26. Inuwa IM, Peet M, Williams MA. 2005. QSAR modeling and transmission electron microscopy stereology of altered mitochondrial ultrastructure of white blood cells in patients diagnosed as schizophrenic and treated with antipsychotic drugs. Biotech Histochem 80:133-137.
27. Iwamoto K, Bundo M, Kato T. 2005. Altered expression of mitochondria-related genes in postmortem brains of patients with bipolar disorder or schizophrenia, as revealed by largescale DNA microarray analysis. Hum Mol Gen 14:241-253.
28. Karry R, Klein E, Ben Shachar D. 2004. Mitochondrial complex I subunits expression is altered in schizophrenia: a postmortem study. Biol. Psychiatry 55:676-684.
29. Kung L, Roberts RC. 1999. Mitochondrial pathology in human schizophrenic striatum: a postmortem ultrastructural study. Synapse 31:67-75.
30. Kettenmann H, Ransom BR. 2005. Neuroglia. 2nd ed. Oxford: Oxford University Press.
31. Koehler RC, Gebremedhin D, Harder DR. 2006. Role of astrocytes in cerebrovascular regulation. J Appl Physiol 100: 307-317.
32. Kolomeets NS, Orlovskaya DD, Rachmanova VI, Uranova NA. 2005. Ultrastructural alterations in hippocampal mossy fiber synapses in schizophrenia (a postmortem morphometric study). Synapse 57:47-55.
33. Kolomeets NS, Orlovskaya DD, Uranova NA. 2007. Decreased numerical density of ca3 hippocampal mossy fiber synapses in schizophrenia. Synapse 61:615-621.
34. Kondziella D, Brenner E, Eyjolfsson EM, Markinhuhta KR, Carlsson ML, Sonnewald U. 2006. Glial neuronal interactions are impaired in the schizophrenia model of repeated MK801 exposure. Neuropsychopharmacology 31:1880-1887.
35. Lalo U, Pankratov Y, Kirchhoff F, North RA, Verkhratsky A. 2006. NMDA receptors mediate neuron-to-glia signaling in mouse cortical astrocytes. J Neurosci 26:2673-2683.
36. Magistretti PJ, Pellerin L. 1999. Cellular mechanisms of brain energy metabolism and their relevance to functional brain imaging. Phil Trans R Soc London B 354:1155-1163. (Pubitemid 29400898)
37. Medoff DR, Holbomb HH, Lahti AC, Tamminga CA. 2001. Probing the human hippocampus using rCBF: contrasts in schizophrenia. Hippocampus 11:543-550.
38. Ohtani R, Kawashima S. 1983. Reduction of lipofuscin by centrophenoxine and chlorpromazine in the neurons of rat cerebral hemisphere in primary culture. Exp Gerontol 18: 105-112.
39. Peng TI, Greenamyre JT. 1998. Privileged access to mitochondria of calcium influx through N-methyl-D-aspartate receptors. Mol Pharmacol 53:974-980.
40. Pilegaard K, Ladefoged O. 1996. Total number of astrocytes in the molecular layer of the dentate gyrus of rats at different ages. Anal Quant Cytol Histol 18:279-285.
41. Prince JA, Yassin MS, Oreland L. 1997a. Neuroleptic-induced mitochondrial enzyme alterations in the rat brain. J Pharmacol Exp Ther 280:261-267. (Pubitemid 27171411)
42. Prince JA, Yassin MS, Oreland L. 1997b. Normalization of cytochrome-c oxidase activity in the rat brain by neuroleptics after chronic treatment with PCP or methamphetamine. Neuropharmacology 36:1665-1678. (Pubitemid 28085927)
43. Rey M, Schulz P, Costa C, Dick P, Tissot R. 1989. Guidelines for the dosage of neuroleptics. 1: Chlorpromazine equivalents of orally administered neuroleptics. Int Clin Psychopharmacol 4:95-104.
44. Roberts GW, Colter N, Lofthouse R, Bogerts B, Zech M, Crow TJ. 1986. Gliosis in schizophrenia: a survey. Biol Psychiatry 21:1043-1050. (Pubitemid 16016459)
45. Roberts GW, Colter N, Lofthouse R, Johnstone EC, Crow TJ. 1987. Is there gliosis in schizophrenia? Investigation of the temporal lobe. Biol Psychiatry 22:1459-1468. (Pubitemid 17164838)
46. Rosene DL, Van Hoesen GW. 1987.The hippocampal formation of the primate brain. In: Peters A, Jones EG, eds. Cerebral cortex. New York: Plenum Press. p 345-456.
47. Rosoklija G, Toomayan G, Ellis SP, Keilp J, Mann JJ, Latov N, et al. 2000. Structural abnormalities of subicular dendrites in subjects with schizophrenia and mood disorders: preliminary findings. Arch Gen Psychiatry 57:349-356. (Pubitemid 30202325)
48. Rothermundt M, Falkai P, Ponath G, Abel S, Burkle H, Diedrich M, et al. 2004a. Glial cell dysfunction in schizophrenia indicated by increased S100B in the CSF. Mol Psychiatry 9:897-899. (Pubitemid 39381953)
49. Rothermundt M, Ponath G, Glaser T, Hetzel G, Arolt V. 2004b. S100B serum levels and long-term improvement of negative symptoms in patients with schizophrenia. Neuropsychopharmacology 29:1004-1011. (Pubitemid 38526800)
50. Roy D, Pathak DN, Singh R. 1984. Effects of chlorpromazine on the activities of antioxidant enzymes and lipid peroxidation in the various regions of aging rat brain. J Neurochem 42: 628-633. (Pubitemid 14198942)
51. Schroeter ML, Abdul-Khaliq H, Fruhauf S, Hohne R, Schick G, Diefenbacher A, et al. 2003. Serum S100B is increased during early treatment with antipsychotics and in deficit schizophrenia. Schizophr Res 62:231-236. (Pubitemid 36773932)
52. Smith SJ. 1998. Glia help synapses form and function. Curr Biol 8:R158-160.
53. Steffek AE, Haroutunian V, Meador-Woodruff JH. 2006. Serine racemase protein expression in cortex and hippocampus in schizophrenia. Neuroreport 17:1181-1185. (Pubitemid 44051409)
54. Streck EL, Rezin GT, Barbosa LM, Assis LC, Grandi E, Quevedo J. 2007. Effect of antipsychotics on succinate dehydrogenase and cytochrome oxidase activities in rat brain. Naunyn Schmiedebergs Arch Pharmacol 376:127-133.
55. Sweatt JD. 2004. Hippocampal function in cognition. Psychopharmacology (Berlin) 174:99-110.
56. Tamminga CA, Thaker GK, Buchanan R, Kirkpatrick B, Alphs LD, Chase TN, et al. 1992. Limbic system abnormalities identified in schizophrenia using positron emission tomography with fluorodeoxyglucose and neocortical alterations with deficit syndrome. Arch Gen Psychiatry 49:522-530.
57. Tamminga CA. 2006. The neurobiology of cognition in schizophrenia. J Clin Psychiatry 67:e11.
58. Tsai G, Passani LA, Slusher BS, Carter R, Baer L, Kleinman JE, Coyle JT. 1995. Abnormal excitatory neurotransmitter metabolism in schizophrenic brains. Arch Gen Psychiatry 52: 829-836.
59. Uranova NA, Casanova MF, DeVaughn NM, Orlovskaya DD, Denisov DV. 1996. Ultrastructural alterations of synaptic contacts and astrocytes in postmortem caudate nucleus of schizophrenic patients. Letter to the Editor. Schizophr Res 22:81-83.
60. Uranova N, Orlovskaya D, Vikhreva O, Zimina I, Kolomeets N, Vostrikov V, Rachmanova V. 2001. Electron microscopy of oligodendroglia in severe mental illness. Brain Res Bull 55: 597-610. (Pubitemid 32888378)
61. Uranova N, Bonartsev P, Brusov O,Morozova M, Rachmanova V, Orlovskaya D. 2007. The ultrastructure of lymphocytes in schizophrenia. World J Biol Psychiatry 8:30-37. (Pubitemid 46291199)
62. Velakoulis D,Wood SJ,Wong MT,McGorry PD, Yung A, Phillips L, et al. 2006. Hippocampal and amygdala volumes according to psychosis stage and diagnosis: a magnetic resonance imaging study of chronic schizophrenia, first-episode psychosis, and ultra-high-risk individuals. Arch Gen Psychiatry 63:139-149.
63. Webster MJ, O'Grady J, Kleinman JE, Weickert CS. 2005. Glial fibrillary acidic protein mRNA levels in the cingulate cortex of individuals with depression, bipolar disorder and schizophrenia. Neuroscience 133:453-461.
64. Weinberger DR. 1999. Cell biology of the hippocampal formation in schizophrenia. Biol Psychiatry 45:395-402.
65. Weis S, Llenos IC, Dulay JR, Verma N, Sabunciyan S, Yolken RH. 2007. Changes in region- and cell type-specific expression patterns of neutral amino acid transporter 1 (ASCT-1) in the anterior cingulate cortex and hippocampus in schizophrenia, bipolar disorder and major depression. J Neural Transm 114:261-271.